Amgen Stock News

The FDA has approved AstraZeneca plc (NASDAQ: AZN ) / Amgen Inc''s (NASDAQ: AMGN ) Tezspire (tezepelumab-ekko) as add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. Tezspire was approved following a Priority Review by the agency and based on the … Full story available on Benzinga.com

(RTTNews) - AstraZeneca (AZN.L, AZN) and Amgen''s Tezspire or tezepelumab-ekko has been approved in the US for the add-on maintenance treatment of adult and paediatric patients aged 12 years and older with severe asthma. AstraZeneca noted that Tezspire was approved following a Priority Review by the US Food and Drug Administration (FDA) and

This article was originally published on TipRanks.com Biopharmaceutical company Amgen Inc. The post Amgen Bags FDA Approval for Tezspire to Treat Severe Asthma appeared first on Smarter Analyst .

The FDA has approved AstraZeneca plc (NASDAQ: AZN) / Amgen Inc's (NASDAQ: AMGN) Tezspire (tezepelumab-ekko) as add-on maintenance treatment of adult and pediatric patients aged 12 years and older

AstraZeneca PLC (LSE:AZN) said its Tezspire drug, developed in collaboration with Amgen, Inc, has been approved in the US for treatment of severe asthma in patients older than 12 years. Tezspire (te

Biotech stocks reversed course and advanced solidly in the week ending Dec. 17, as an increase in risk aversion pushed investors to buy into defensive stocks. The sector also drew strength from some positive stock-specific news. Among the regulatory decisions for the week, the Food and Drug Administration gave the green light to argenx SE''s (NASDAQ: ARGX ) efgartigimod for the treatment of generalized myasthenia gravis. AstraZeneca plc (NASDAQ: AZN ) and Amgen, Inc. (NASDAQ: AMGN ) announced an FDA nod for their Tezspire as a treatment option for severe asthma for those aged 12 years and older. Bristol-Myers Squibb Company ''s (NYSE: BMY ) Orencia was approved for the prophylactic treatment of acute graft-versus-host disease. Calliditas Therapeutics AB (publ) (NASDAQ: CALT ) scored an FDA win for Tarpeyo, the first-approved treatment to reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression. Galera Therapeutics, Inc. (NASDAQ: Full story available on Benzinga.

First Long Island Investors LLC raised its stake in Amgen Inc. (NASDAQ:AMGN) by 3.1% in the third quarter, HoldingsChannel reports. The institutional investor owned 118,793 shares of the medical research companys stock after buying an additional 3,524 shares during the quarter. Amgen makes up approximately 2.2% of First Long Island Investors LLCs portfolio, making the []

Motco grew its holdings in Amgen Inc. (NASDAQ:AMGN) by 37.5% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 356 shares of the medical research companys stock after buying an additional 97 shares during the period. Motcos holdings in Amgen were worth $76,000 as of []

Good Life Advisors LLC raised its position in shares of Amgen Inc. (NASDAQ:AMGN) by 29.7% in the 3rd quarter, Holdings Channel.com reports. The firm owned 1,324 shares of the medical research companys stock after acquiring an additional 303 shares during the quarter. Good Life Advisors LLCs holdings in Amgen were worth $282,000 as of its []

Emfo LLC increased its stake in Amgen Inc. (NASDAQ:AMGN) by 8.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 8,562 shares of the medical research companys stock after purchasing an additional 659 shares during the quarter. Amgen accounts for 1.6% of Emfo LLCs portfolio, []

Carderock Capital Management Inc. decreased its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 88.3% in the 3rd quarter, Holdings Channel.com reports. The firm owned 2,478 shares of the medical research companys stock after selling 18,769 shares during the quarter. Carderock Capital Management Inc.s holdings in Amgen were worth $527,000 as of its most recent []

As we have previously discussed, on February 11, 2021, the Federal Circuit decided Amgen Inc. et al. v. Sanofi, Aventisub LLC, et al. The Federal Circuit affirmed the district court’s grant of JMOL that Amgen’s Repatha® patents (U.S. Patent Nos. 8,829,165 and 8,859,741) were invalid for lack of enablement. The claims at issue cover a genus of monoclonal antibodies that bind to the proprotein convertase subtilisin/kexin type 9 (“PCSK9”) enzymes…... By: Rothwell, Figg, Ernst & Manbeck, P.C.

Parthenon LLC reduced its position in shares of Amgen Inc. (NASDAQ:AMGN) by 16.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,177 shares of the medical research company’s stock after selling 224 shares during the quarter. Parthenon LLC’s holdings in […]

DUBLIN--(BUSINESS WIRE)--The "TRAIL Receptor 2 Agonists - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com''s offering. This report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in TRAIL receptor 2 agonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further high